M&A

The winners and losers from JPM 2019
Biopharma Dive
Fri, 01/11/19 - 11:51 am
JPMHC 2019
Loxo Oncology
SAGE Therapeutics
Amarin
FDA
M&A
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
Hospital Mergers Get Even Bigger As Seller Size Hits $400M
Forbes
Fri, 01/11/19 - 10:17 am
M&A
hospitals
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Fri, 01/11/19 - 09:58 am
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Thu, 01/10/19 - 12:31 pm
Editas
CRISPR
GSK
Tesaro
Clovis Oncology
M&A
AbbVie
JPMHC 2019
Does Eli Lilly's $8 Billion Splurge Make Array BioPharma a Buy Now?
Motley Fool
Wed, 01/9/19 - 09:43 am
Eli Lilly
Loxo Oncology
Array Biopharma
M&A
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Takeda’s Shire takeover could herald new era of pharma M&A
Pharmaforum
Wed, 01/9/19 - 09:18 am
M&A
Takeda
Shire
taxes
Pfizer
Class Action Lawsuit Aims to Halt GSK Acquisition of Tesaro
BioSpace
Tue, 01/8/19 - 07:10 pm
GSK
M&A
Tesaro
shareholders
With mega merger season in full swing, Takeda officially swallows Shire
Endpoints
Tue, 01/8/19 - 07:09 pm
Takeda
Shire
M&A
JPM: Why hasn't Merck been making deals? It's not for lack of trying, CEO says
Fierce Pharma
Tue, 01/8/19 - 10:37 am
Merck
Pharma CEOs
Ken Frazier
M&A
JPMHC 2019
Is Eli Lilly Overpaying for Loxo Oncology?
Motley Fool
Tue, 01/8/19 - 09:30 am
Eli Lilly
Loxo Oncology
M&A
Vitrakvi
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Tue, 01/8/19 - 09:12 am
Gilead Sciences
JPMHC 2019
HIV
hepatitis C
M&A
Daniel O'Day
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Motley Fool
Tue, 01/8/19 - 12:43 am
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
Celgene invested $30M in NantCell weeks before BMS bid
BioCentury
Tue, 01/8/19 - 12:41 am
Celgene
NantCell
Bristol-Myers Squibb
M&A
Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics
Stat
Mon, 01/7/19 - 10:09 am
Eli Lilly
Loxo Oncology
M&A
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
Motley Fool
Sun, 01/6/19 - 11:08 pm
Bristol-Myers Squibb
Celgene
M&A
AbbVie records $4B impairment on Stemcentrx deal
BioCentury
Sun, 01/6/19 - 07:49 pm
AbbVie
Stemcentrx
M&A
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
Forbes
Sat, 01/5/19 - 03:04 pm
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
BMS CEO Giovanni Caforio Lays out Reasoning for $74 Billion Acquisition of Celgene
BioSpace
Sat, 01/5/19 - 03:08 pm
Bristol-Myers Squibb
M&A
Giovanni Caforio
Celgene

Pages